medicine
New STOA study on better access to medicines in the EU
Interview with study author Simona Gamba When it comes to less profitable markets such as rare diseases, paediatric diseases or antimicrobials, medicines in the EU could be hard to come by, both in terms of price and availability. On Thursday 19 October, Senior Assistant Professor Simona Gamba (University of Milan, Italy) presented the study "Improving ...
Interview with Prof. Francesco Imperi on new strategies to fight antimicrobial resistance
When bacteria, viruses, fungi and parasites no longer respond to medicines: this is set to become one of the major health threats of the 21st century. Francesco Imperi, Associate Professor of Microbiology at Roma Tre University (Italy), is working on novel strategies to tackle this antimicrobial resistance (AMR), more specifically in multidrug resistant bacterial human ...
EU Project : CONCISE
CONCISE aims to generate a European-wide debate on science communication, involving a wide array of stakeholders, from media outlets to policy makers, from scientists to business companies, from science communicators to civil society organisations. CONCISE aims at providing qualitative knowledge through citizen consultation on the means/channels (media and social networks, life experience, relatives, religion, political ...
A scientist’s opinion : Interview with Renate Heinisch about new technologies in medicine
Interview with Renate Heinisch, pharmacist, former vice-chair of Science and Technology Options Assessment (STOA) panel and now member of the European Economic and Social Committee New technologies are going to deeply affect healthcare. Will citizens be ready? Renate Heinisch: We must consider that scientific and technological innovations accompanied all of human history, since ancient times. ...
A scientist’s opinion : Interview with Professor Michel Goldman about new technologies in medicine
Interview with Michel Goldman, founder of the Institute for Interdisciplinary Innovation in Healthcare (I3H) and former Executive Director of the Innovative Medicines Initiative (IMI). How was the idea of I3H born? Michel Goldman: At the Innovative Medicines Initiative (IMI) the main goal was to bring together pharmaceutical industry and universities, patient organizations, and regulators, to ...
